What Is Nutropin GPS?

Support is a phone call away
1-866-NUTROPIN (1-866-688-7674) or Fax at 1-800-545-0612

Get personalized, one-on-one help from the Nutropin Growing Patient Support (GPS)™ Program

Whether it's getting your treatment up and running quickly, help navigating the insurance maze, or getting your growth hormone (GH) therapy questions answered, Nutropin GPS has an ongoing commitment to support you and your healthcare team through every step of treatment.

Nutropin GPS is made up of people and programs to support you throughout your Nutropin therapy.

Nurse Hotline

To get answers to your questions, call

Injection Training

One-on-one instruction from a trained nurse on how to use your Nutropin device.

Dedicated Case Manager

A GPS Case Manager is there to assist eligible patients with insurance questions and getting access to therapy.

Can I receive assistance while I wait for insurance approval?


We know the process for insurance verification and authorization takes time. Eligible patients may receive medicine while their insurance coverage is evaluated. To learn how to get started read Getting Started with Nutropin GPS.

My insurance covers Nutropin, but can I receive help with my co-pay?

Nutropin GPS Co-pay Card Program

By using the Nutropin Co-pay Card program, the patient
 acknowledges and confirms that at the time of usage, (s)he is currently eligible and
 meet the criteria set forth in the terms and conditions described.

This Co-pay Card is valid ONLY for patients with commercial (private or non governmental)
 insurance. It is not valid for patients who are Government
 beneficiaries or whose medications are covered, in whole or in part, under
 Medicaid, Medicare Part A, B, C and/or D, TRICARE, CHAMPUS, Puerto Rico
 Government Health Insurance Plan, or any other state or federal healthcare
 program. Patients who become Government beneficiaries during their enrollment
 period will no longer be eligible for the program as of the date they become a
 Government beneficiary.

This Co-pay Card program is not health insurance or a benefit plan. Distribution or
 use of the Co-pay Card does not obligate use or continuing use of any specific
 product or provider. Patient or guardian is responsible for reporting the receipt of all
 Co-pay Card program benefits or reimbursement received, to any insurer, health
 plan, or other third party who pays for or reimburses any part of the prescription
 filled using the
Co-pay Card program, as may be required.

The Co-pay Card is not valid for medications the patient receives for free or that are
 eligible to be reimbursed by private insurance plans or other healthcare or
 pharmaceutical assistance programs (such as: GATCF or any other charitable
 organization) that reimburse the patient in part or for the entire cost of his/her
 medication. Patient, guardian, pharmacist, prescriber and any other person using
 the Co-pay Card agree not to seek reimbursement for all or any part of the benefit
 received by the recipient through the offer.

The Co-pay Card will be accepted by participating pharmacies, physician offices or
 hospitals. To qualify for the benefits of this Co-pay Card program, the patient may
be required to pay out-of-pocket expenses for each treatment. Once enrolled, this
 Co-pay Card program will not honor claims with date of service or medication
 dispensing that precede program enrollment by more than 120 days. This Co-pay
 Card is only available with a valid prescription and cannot be combined with any
 other rebate/coupon, free trial, or similar offer for the specified prescription. Use of
 this Co-pay Card must be consistent with all relevant health insurance requirements
 and payer agreements. Participating patients, pharmacies, physician offices and hospitals are obligated to inform third-party payers about the use of the Co-pay Card as provided for under the applicable insurance or as otherwise required by contract or law. The Co-pay Card may not be sold, purchased, traded or offered for
 sale, purchase or trade. The Co-pay Card is limited to 1 per person during this
 offering period and is not transferable. This program expires within 12 months from
 enrollment. This program is not valid where prohibited by law. For Massachusetts’
 residents, the Co-pay Card is not valid for any prescription drug that has an AB 
rated generic equivalent as determined by the United States Food and Drug
 Administration. For Massachusetts’ residents, this program shall expire on or
 before July 1, 2017

The patient or their guardian must be 18 years or older to receive Co-pay Card
 program assistance. This Co-pay Card program is: (1) Void if the card is
 reproduced; (2) Void where prohibited by law; (3) only valid in the United States
 and Puerto Rico; and (4) only valid for Genentech products. Healthcare providers
 may not advertise or otherwise use the program as a means of promoting their
 services or Genentech’s products to patients. Genentech, Inc. reserves the right to
 rescind, revoke, or amend the program without notice at any time.

For more information review the co-pay brochure.

Nutropin GPS Co-Pay Brochure - Download PDF (4.3 MB)

To learn how to get started read Getting Started with Nutropin GPS.

What other co-pay support options are available to me?

Independent Co-Pay Assistance Program

For those who don't qualify for the Nutropin GPS Co-Pay Card Program, we can also refer you to a co-pay foundation for help with your co-pay. You may be referred to a co-pay assistance program if you have:

  • Public insurance, such as Medicare or Medicaid
  • Private insurance

Patients enrolled in Medicare Part D may be eligible to apply for co-pay assistance, including fees associated with true out-of-pocket (TrOOP) expenses.

To learn how to get started read Getting Started with Nutropin GPS.

I have no insurance or Nutropin is not covered by my plan. Can you help?

Genentech Access To Care Foundation (GATCF)

GATCF helps eligible patients who meet specific medical and financial criteria receive Nutropin AQ® free of charge.

GATCF provides free medicine to eligible patients who are uninsured, rendered uninsured by payer denial or underinsured. To qualify, patients meet specific financial and medical criteria.

Eligibility Criteria

Patient is without coverage for Genentech medicine Patient household AGI is
Patient household AGI is
(uninsured or rendered uninsured by payer denial) >$100,000–≤$150,000
and the out-of-pocket (OOP) costs for his/her Genentech medicines account for ≥5% of his/her annual household AGI
Patient has coverage for Genentech medicines Patient household AGI is

and the OOP costs for his/her Genentech medicines account for ≥5% of his/her annual household AGI

All patient assistance options have been exhausted, including Genentech brand-specific co-pay cards and support from co-pay assistance foundations supporting the patient’s disease state
Patient must meet certain medical criteria as established by independent advisory board Patient has coverage for Genentech medicines

We cannot guarantee you will get help from a co-pay foundation. The co-pay foundations each have their own rules, including financial rules. Genentech does not influence or control these co-pay foundations. But Nutropin GPS can help you. We can refer you to an appropriate co-pay foundation. We can also help with the application process.


Nutropin AQ® [somatropin (rDNA origin) injection] is human growth hormone that is available by prescription only.

Doctors prescribe Nutropin therapy for children and teenagers who are short or growing slowly because they:

  • Do not make enough growth hormone on their own
  • Have idiopathic short stature, which means they are shorter than 98.8% of other children of the same age and sex; are growing at a rate not likely to allow them to reach normal adult height; and no other cause of short stature can be found
  • Have Turner syndrome
  • Have chronic kidney disease (CKD) up to the time of kidney transplant

Doctors prescribe Nutropin therapy for adults who have growth hormone deficiency that began either in:

  • Adulthood as a result of pituitary disease, diseases of the hypothalamus, surgery, radiation therapy, or trauma; or
  • Childhood. Patients treated for growth hormone deficiency in childhood, whose bones have stopped growing, should be reevaluated to see if they need to continue with growth hormone therapy

Your doctor will test to see if growth hormone is right for you.


Nutropin therapy and your safety:

Please read this important safety information carefully. Then, if you have any questions, talk with your doctor.


  • Patients having serious complications after undergoing open heart surgery, abdominal surgery, serious injuries involving many body systems, or life-threatening breathing problems. Deaths have been reported in such cases
  • Children who have Prader-Willi syndrome (PWS) and are very overweight or have a history of severe breathing problems. Deaths have been reported in children with PWS who are very overweight, have a history of blocked upper airways, sleep apnea (pauses in breathing during sleeping), or other severe breathing problems
  • Patients who have active cancer. Because growth hormone deficiency can be an early sign of some tumors in the brain or pituitary gland, the presence of these types of tumors should be ruled out by your doctor before you start Nutropin therapy
  • Adults or children with certain types of eye disease caused by diabetes
  • Children and teenagers whose bones have finished growing
  • Patients who are allergic to somatropin, the active ingredient in Nutropin therapy. Reactions at the injection site are the most common allergic reactions

What should you tell your doctor before starting Nutropin therapy?

  • If you take cyclosporine, hormone replacement therapy, insulin or other diabetes medications, drugs containing steroids, or drugs for seizures. These medications may need to be adjusted during Nutropin therapy
  • If you had cancer as a child. An increased risk of a new tumor, particularly certain brain tumors, has been reported in patients taking Nutropin therapy. If you have pre-existing tumors or growth hormone deficiency caused by abnormal tissue in the brain, you should be watched closely for the worsening or return of this condition
  • If you have diabetes, risk factors for diabetes, or impaired glucose tolerance. If so, your doctor should monitor your blood sugar closely during Nutropin therapy. New cases of type 2 diabetes have been reported in patients taking Nutropin therapy
  • If you have hypopituitarism (an inability of the pituitary gland to produce sufficient hormones) and are on standard hormone replacement therapy. In that case, your doctor should monitor your hormone replacement therapy closely while you are taking Nutropin therapy
  • If you are pregnant, nursing, or plan to become pregnant. It is not known whether Nutropin is excreted in human milk. Nutropin therapy should be used during pregnancy only when clearly needed

While taking Nutropin, contact your doctor immediately if you experience:

  • Changes in vision, a bad headache, or nausea with or without vomiting. This may be a sign of increased pressure in the brain
  • A limp or have hip or knee pain
    • A fracture in the ball of the hip joint can occur in children who have endocrine problems and in children who have rapid growth
    • Children with growth failure due to CKD should be examined periodically for evidence of loss of bone minerals. Hip x-rays should be taken before starting Nutropin therapy in these children
  • Progression of scoliosis (curvature of the spine) that can occur in children who have rapid growth. Nutropin therapy has not been shown to increase the occurrence of this condition
  • Any allergic reaction you experience to the injection of Nutropin therapy
  • Abdominal pain. Cases of pancreatitis (inflammation of the pancreas) have been reported rarely in children and adults receiving Nutropin therapy

Other important information about Nutropin

  • Adults may retain water during Nutropin therapy. This may be brief but may increase with higher doses of Nutropin therapy
  • Patients should have their thyroid function tested periodically during Nutropin therapy. Thyroid hormone treatment may need to be started or adjusted
  • Patients should be sure to inject Nutropin at a different recommended place on their body each time to avoid tissue breakdown. A doctor or nurse should provide injection training and supervise the first injection
  • The use of Nutropin therapy has not been studied in patients over 65 years of age. Elderly patients may be more sensitive to Nutropin therapy and may experience more side effects
  • Patients with Turner syndrome should be monitored closely by a doctor for ear infections and cardiovascular problems during Nutropin therapy
  • Nutropin therapy may affect the body’s ability to process two hormones, cortisol and cortisone, which can lead to a condition called hypoadrenalism (under activity of the adrenal gland). In that case, glucocorticoid replacement therapy may need to be prescribed

What are common possible side effects of Nutropin therapy?

Common side effects reported in adults and children taking Nutropin therapy include injection site reactions. Additional common side effects in adults include swelling, joint pain, and carpal tunnel syndrome.

You may report side effects to FDA at (800) FDA-1088 or www.fda.gov/medwatch.  You may also report side effects to Genentech at (888) 835-2555.

How should you store Nutropin?

Nutropin must be kept refrigerated (36° to 46°F [2° to 8°C]). Do not freeze. Cartridges and NuSpin pens must be used within 28 days of initial use. Throw away any unused Nutropin after 28 days of initial use. Before giving an injection, check the manufacturer's expiration date on the cartridge or pen. Do not use if it has expired. Do not inject medication if the solution is cloudy.

Please see accompanying Nutropin full Prescribing Information for additional Important Safety Information.

Back to Top